Tranexamic Acid Should NOT Be Used for Threatened Abortion
There is no evidence supporting the use of tranexamic acid in threatened abortion, and it should not be used for this indication. The available evidence exclusively addresses tranexamic acid for post-partum hemorrhage (bleeding after delivery), not for bleeding during early pregnancy or threatened abortion.
Critical Distinction: Post-Partum vs. Early Pregnancy Bleeding
The provided guidelines are specific to post-partum hemorrhage - bleeding that occurs after birth. The WHO strongly recommends tranexamic acid only for clinically diagnosed post-partum hemorrhage (>500 mL after vaginal birth or >1000 mL after cesarean section) within 3 hours of delivery 1. This is fundamentally different from threatened abortion, which occurs during early pregnancy before delivery.
Why This Matters
Threatened abortion involves a viable pregnancy with vaginal bleeding before 20 weeks gestation. The pathophysiology, timing, and clinical context are completely different from post-partum hemorrhage:
- Different mechanism: Threatened abortion involves potential placental separation or decidual bleeding in early pregnancy, not the hyperfibrinolysis that occurs after placental delivery
- Different gestational age: Early pregnancy (typically <12-20 weeks) versus immediate post-delivery period
- Different outcomes at stake: Pregnancy continuation and fetal viability versus maternal hemorrhage control
Limited and Inadequate Evidence for Early Pregnancy
While one small Russian study from 2007 suggested tranexamic acid might help arrest bleeding in threatened abortion 2, this represents extremely weak evidence - a single non-randomized study with unclear methodology. A recent 2026 scoping review explicitly concluded that "evidence for TXA use in early pregnancy is limited, with small, low-quality studies" and that "larger, high-quality trials are needed to determine safety and efficacy" 3.
Safety Concerns in Early Pregnancy
The FDA drug label notes important uncertainties 4:
- Two infant deaths with structural abnormalities occurred when tranexamic acid was used during conception or first trimester
- The risk of major birth defects with tranexamic acid during pregnancy "is not clear"
- Tranexamic acid crosses the placenta at concentrations equal to maternal blood
- Studies reported fetal/neonatal issues including low Apgar scores, neonatal sepsis, low birth weight, and preterm birth at 22-36 weeks
The FDA explicitly states: "It is not known whether tranexamic acid use in pregnant women may cause a drug-associated risk of miscarriage or adverse maternal or fetal outcomes" 4.
Clinical Recommendation
Do not use tranexamic acid for threatened abortion. The standard management of threatened abortion includes:
- Pelvic rest and activity modification
- Serial ultrasound monitoring for fetal viability
- Progesterone supplementation in select cases (if corpus luteum insufficiency suspected)
- Expectant management with close follow-up
If bleeding is severe enough to cause hemodynamic instability in early pregnancy, this represents a different emergency (likely miscarriage in progress, ectopic pregnancy, or other pathology) requiring urgent obstetric evaluation, not empiric tranexamic acid administration.
Common Pitfall to Avoid
Do not extrapolate the strong evidence for tranexamic acid in post-partum hemorrhage to early pregnancy bleeding. These are distinct clinical entities requiring different management approaches. The timing, mechanism, and risk-benefit calculations are fundamentally different.